Lynn G. Feun
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Lynn G. Feun

Hematology Oncology | Hematology | Oncology
University Of Miami
1601 Nw 12th Ave, 
Miami, FL 
Accepting New Patients
Offers Telehealth
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
University Of Miami
1601 Nw 12th Ave, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lynn Feun is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Feun is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Melanoma, Liver Cancer, Melanoma of the Eye, and Fibrolamellar Carcinoma. Dr. Feun is currently accepting new patients.

His clinical research consists of co-authoring 54 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

UNIVERSITY OF MIAMI
1601 Nw 12th Ave, Miami, FL 33136
Other Locations
UNIVERSITY OF MIAMI
1611 Nw 12 Th Ave, Jackson Memorial Hospital, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma
Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 15, 2023
Intervention Type: Drug
Study Drugs: AEB071, BYL719
Study Phase: Phase 1
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 1
Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)
Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: November 12, 2020
Intervention Type: Drug
Study Phase: Phase 2
Proof of Concept Study of Vorinostat, A Histone Deacetylase Inhibitor, in Patients With Class 2 High Risk Uveal Melanoma
Proof of Concept Study of Vorinostat, A Histone Deacetylase Inhibitor, in Patients With Class 2 High Risk Uveal Melanoma
Enrollment Status: Withdrawn
Publish Date: February 06, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
View 9 Less Clinical Trials

54 Total Publications

Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.
Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.
Journal: Cancers
Published: August 08, 2025
Similar Doctors
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Marshall R. Posner
Oncology
Elite in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Marshall R. Posner
Oncology

Cancer Center Of South Florida PLLC

1630 S Congress Ave, Suite 200, 
Palm Springs, FL 
 (59.0 miles away)
561-253-3980
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Marshall Posner is an Oncologist in Palm Springs, Florida. Dr. Posner is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Gland Tumors, Laryngeal Cancer, Olfactory Neuroblastoma, and Tissue Biopsy. Dr. Posner is currently accepting new patients.

Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Abraham Schwarzberg
Hematology | Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Abraham Schwarzberg
Hematology | Oncology

Cancer Center Of South Florida PLLC

1630 S Congress Ave, Suite 200, 
Palm Springs, FL 
 (59.0 miles away)
561-253-3980
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Abraham Schwarzberg is a Hematologist and an Oncologist in Palm Springs, Florida. Dr. Schwarzberg is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Matthen Mathew
Oncology | Hematology
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Matthen Mathew
Oncology | Hematology

Brrh Oncology, LLC

701 Northwest 13th St, 2nd Floor, 
Boca Raton, FL 
 (40.2 miles away)
561-955-6400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthen Mathew is an Oncologist and a Hematologist in Boca Raton, Florida. Dr. Mathew is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy. Dr. Mathew is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Feun's expertise for a condition
ConditionClose
View All 24 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile